Humana (HUM)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
$396.58+0.50%
Close 2026-07-08 · 1-day change
Reading HUM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HUM free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
Reading HUM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HUM free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
Humana is positioned as a durable compounder in the healthcare sector. The current thesis state reflects a strong recent financial performance, but management execution has been volatile, creating uncertainty.
The market currently prices Humana as cheap compared to its peers, with a low expectations gap. This suggests that investors may be anticipating some challenges ahead, but not significant negative developments.
Fundamentals may show continued strength in the near term, as management has reaffirmed earnings guidance. However, the company's recent net income decline and the need for significant revenue growth present challenges.
The thesis hinges on management's ability to maintain guidance and the performance of sector bellwethers like UNH, CVS, and ELV. Any cuts to guidance or negative earnings reports from these companies could impact Humana's trajectory.
Overall, Humana's outlook for the next 1 to 3 years is cautious but stable, with key risks to monitor. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the positive outlook. Recent guidance and acquisition interest also enhance growth potential. There are no new threats to the thesis.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This report will provide updates on financial performance and growth strategies. It is crucial for assessing future guidance.
Confirms one read:Earnings report shows revenue growth exceeding $128 billion for FY 2025.
Confirms the other:Earnings report shows revenue below $128 billion for FY 2025.
Why it matters: Keeping this EPS guidance shows Humana's commitment to strong earnings. A failure to maintain it could signal deeper issues.
Confirms one read:Humana reaffirms its EPS guidance of at least $9.00 during investor meetings.
Confirms the other:Humana cuts its EPS guidance to under $9.00 in future updates.
Why it matters: Lawsuit results can change financial performance and guidance. Bad results may lower earnings expectations.
Confirms:Lawsuit results are good, so management keeps guidance the same.
Disproves:Lawsuit results cause a drop in EPS guidance.
Why it matters: More Medicare Advantage members mean more revenue. It shows how well Humana gets new customers.
Confirms:Membership growth exceeds 25% year over year as projected.
Disproves:Membership growth falls below 20% year over year.
Why it matters: A successful buyback shows confidence in the company's value. It can help share prices.
Confirms:Humana announces it has finished its share buyback program and shares bought back.
Disproves:Humana stops or cancels the share buyback program without clear reasons.
Why it matters: This outcome affects Humana's quality bonus payments and total revenue. A good ruling could help finances.
Confirms one read:The court rules in favor of Humana on Star Ratings. This allows for possible bonus recovery.
Confirms the other:The court rules against Humana. This confirms the drop in Star Ratings and affects bonus payments.
Why it matters: Raising revenue guidance shows growth. This can help investor confidence in the company.
Confirms:Humana announces an increase in FY 2025 revenue guidance to at least $128 billion.
Disproves:Humana keeps FY 2025 revenue guidance under $128 billion, showing slower growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Updates on the share buyback program can signal management's confidence in the stock. It may also affect share price.
Confirms:Management announces an increase in the share buyback amount or pace.
Disproves:Management stops or cuts the share buyback program.